市場調查報告書
商品編碼
1465120
電穿孔設備市場:按應用、最終用戶分類 - 2024-2030 年全球預測Electroporation Instrument Market by Application (Biomedical Research, Protein Production), End-user (Academic & Research Institutions, Pharmaceutical & Biotechnology Companies) - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年電穿孔設備市場規模為2.6706億美元,預計2024年將達2.810億美元,2030年將達3.8844億美元,複合年成長率為5.49%。
電穿孔設備是專為電穿孔過程設計的先進設備,電穿孔是一種用於增加細胞膜滲透性的微生物技術。該過程透過向細胞施加電場,將 DNA、RNA、蛋白質和化學物質等物質引入細胞中。對合成基因不斷成長的需求,以及對個人化醫療日益成長的興趣,正在加速市場創新。然而,與先進電穿孔技術相關的高成本以及精確控制電參數以避免細胞損傷的需求正在阻礙市場成長。此外,在製藥和生物技術公司大量投資的支持下,電穿孔技術的進步正在為市場成長創造利潤豐厚的機會。
主要市場統計 | |
---|---|
基準年[2023] | 26706萬美元 |
預測年份 [2024] | 2.81 億美元 |
預測年份 [2030] | 38844萬美元 |
複合年成長率(%) | 5.49% |
應用慢性病的增加推動電穿孔設備在生物醫學研究的應用
在生物醫學研究領域,電穿孔對於將外源核酸引入細胞極為重要。這個過程對於基因治療、癌症研究和各種遺傳疾病的研究至關重要。電穿孔後的精確度、效率和細胞活力是關鍵因素。專注於生物醫學研究的實驗室優先考慮提供高通量能力、可自訂的電穿孔參數和最低細胞殺傷率的設備,以確保實驗結果的可靠性和可重複性。電穿孔已成為蛋白質生產領域的重要工具,特別是在重組蛋白質療法的開發中。 DNA 引入宿主細胞的效率對所產生的蛋白質的產量和品質有直接影響。
最終用戶製藥和生物技術公司更喜歡更準確和擴充性的電穿孔設備。
學術和研究機構的一個關鍵需求是經濟實惠、易於使用且多功能的電穿孔系統,該系統可以支援廣泛的研究應用,例如基因功能研究、治療開發和疫苗研究。為了支持大批量遺傳研究和 CRISPR 基因編輯計劃,對能夠同時處理多個樣本的高通量系統的需求不斷成長。製藥和生物技術公司包括從事藥物發現、治療開發和生物技術研究的公司。這些公司優先考慮提供精確性、擴充性以及與藥物篩檢和治療開發現有工作流程整合的能力的電穿孔儀器。高效轉染困難細胞類型(包括原代細胞和幹細胞)是確保新型治療方法(包括基於基因編輯和細胞療法的療法)成功的關鍵要求。
區域洞察
包括美國和加拿大在內的美洲地區專注於生物技術和製藥領域的研發,推動了對電穿孔設備的需求。該市場的特點是對最尖端科技的高投資,並出現了許多創新的電穿孔技術和設備改進。該地區的消費者重視電穿孔設備的可靠性、效率和先進功能。歐盟 (EU) 市場的特點是嚴格的監管標準以及對研究誠信和道德考慮的重視。歐盟國家對電穿孔設備的需求是由先進的醫療保健系統、強大的研究環境以及大量的政府和私人資金所推動的。中國、日本和印度是亞太地區的關鍵地區,政府對生物技術研究投入大量資金,製藥業蓬勃發展,與國際生物技術公司的合作日益增多,推動了電穿孔設備市場的快速擴張。日本市場高度發達,強調創新和品質。
FPNV定位矩陣
FPNV定位矩陣對於評估電穿孔設備市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對電穿孔設備市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,從而在市場上獲得競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4. 競爭評估和情報:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。
5. 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1.電穿孔設備市場的市場規模與預測為何?
2.在電穿孔設備市場的預測期間內,有哪些產品、細分市場、應用和領域需要考慮投資?
3.電穿孔設備市場的技術趨勢與法規結構是什麼?
4.電穿孔設備市場主要供應商的市場佔有率為何?
5.進入電穿孔設備市場合適的型態和策略手段是什麼?
[184 Pages Report] The Electroporation Instrument Market size was estimated at USD 267.06 million in 2023 and expected to reach USD 281.00 million in 2024, at a CAGR 5.49% to reach USD 388.44 million by 2030.
An electroporation instrument is a sophisticated device designed for the process of electroporation, which is a microbiological technique used to increase the permeability of cell membranes. This process allows for the introduction of substances such as DNA, RNA, proteins, & chemicals into the cell by using an electrical field to the cells, creating temporary pores in the membrane through which materials can be introduced. Rising demand for synthetic genes, along with the growing emphasis on personalized medicine, is accelerating innovation in the market. However, high costs associated with sophisticated electroporation technologies and the requirement for precise control over electrical parameters to avoid cell damage impede market growth. Furthermore, advancements in electroporation techniques supported by significant investments from pharmaceutical & biotechnology companies create lucrative opportunities for market growth.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 267.06 million |
Estimated Year [2024] | USD 281.00 million |
Forecast Year [2030] | USD 388.44 million |
CAGR (%) | 5.49% |
Application: Growing prevalence of chronic disorder boost the utilization of electroporation iInstrument in biomedical research
In the realm of biomedical research, electroporation instruments are pivotal for introducing foreign nucleic acids into cells. This process is vital for gene therapy, cancer research, and the study of various genetic disorders. The precision, efficiency, and cell viability rates post-electroporation are crucial factors considered. Laboratories focused on biomedical research prioritize instruments offering high-throughput capabilities, customizable electroporation parameters, and minimal cell mortality to ensure the reliability and reproducibility of experimental results. Electroporation has become an indispensable tool in the field of protein production, particularly in the development of recombinant protein therapeutics. The efficiency of DNA introduction into host cells instantly affects the yield and quality of the produced proteins.
End-user: Pharmaceutical & biotechnology companies prefer electroporation instrument with more precision & scalability
Academic & research institutions' primary needs revolve around affordable, user-friendly, and versatile electroporation systems that can support a wide range of research applications such as gene function studies, therapeutic development, and vaccine research. High-throughput systems that can process multiple samples simultaneously are increasingly in demand to support high-volume genetic research and CRISPR gene-editing projects. Pharmaceutical & biotechnology companies cover companies involved in drug discovery, therapeutic development, and biotechnological research. They prioritize electroporation instruments that offer precision, scalability, and integration capabilities with existing workflows for drug screening and therapeutic development. Efficiency in transfecting challenging cell types, including primary cells and stem cells, is a crucial demand to ensure the success of novel therapies, including those based on gene editing and cell therapy.
Regional Insights
In the American region encompassing the United States and Canada, a significant emphasis on research and development in the biotechnological and pharmaceutical sectors drives demand for electroporation instruments. The market is characterized by high investment in cutting-edge technology, with numerous innovative electroporation techniques and apparatus improvements. Consumers in the region value reliability, efficiency, and advanced features in electroporation instruments. The European Union market is distinguished by stringent regulatory standards and a strong focus on research integrity and ethical considerations. Demand for electroporation instruments in EU countries is driven by advanced healthcare systems, robust research environments, and substantial government and private funding. China, Japan, & India are the major regions in the Asia Pacific region, with their market for electroporation instruments expanding rapidly due to substantial government investment in biotechnology research, a burgeoning pharmaceutical industry, and increasing collaboration with international biotech firms. Japan's market is highly developed, with a strong emphasis on innovation and quality.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Electroporation Instrument Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Electroporation Instrument Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Electroporation Instrument Market, highlighting leading vendors and their innovative profiles. These include ALA Scientific Instruments, Inc., Bertin Technologies SAS, Bio-Rad Laboratories, Inc., BTX by Harvard Bioscience, Inc., Celetrix, LLC, Eppendorf SE, Inovio Pharmaceuticals Inc., Lonza Group Ltd., MaxCyte, Inc., Mirus Bio LLC, and Thermo Fisher Scientific Inc..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Electroporation Instrument Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Electroporation Instrument Market?
3. What are the technology trends and regulatory frameworks in the Electroporation Instrument Market?
4. What is the market share of the leading vendors in the Electroporation Instrument Market?
5. Which modes and strategic moves are suitable for entering the Electroporation Instrument Market?